Evidence map›Paper›PMID 29468354›Full record

ArticleInternational journal of colorectal disease2018

Outcomes and prognostic factors of multimodality treatment for locally recurrent rectal cancer with curative intent.

Thomas G Bird, Samuel Y Ngan, Julie Chu, René Kroon, Andrew C Lynch, Alexander G Heriot

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of colorectal disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
1.8field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Ten-year survival and pattern of recurrence in patients with locally recurrent rectal or sigmoid cancer undergoing resection.Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland · 2024
    Article
  5. Article
  6. Local Recurrences in Rectal Cancer: MRI vs. CT.Diagnostics (Basel, Switzerland) · 2023
    Review
  7. Review
  8. Review
  9. Surgical management of recurrent colon cancer.Journal of gastrointestinal oncology · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Thomas G BirdDepartment of Radiation Oncology, Peter MacCallum Cancer Centre, Locked Bag 1, A'Beckett Street, Melbourne, Victoria, 8006, Australia. Thomas.Bird@nhs.net.ORCID http://orcid.org/0000-0002-8504-8737
Samuel Y NganDepartment of Radiation Oncology, Peter MacCallum Cancer Centre, Locked Bag 1, A'Beckett Street, Melbourne, Victoria, 8006, Australia.
Julie ChuDepartment of Radiation Oncology, Peter MacCallum Cancer Centre, Locked Bag 1, A'Beckett Street, Melbourne, Victoria, 8006, Australia.
René KroonCentre for Biostatistics and Clinical Trials, Peter MacCallum Cancer Centre, Melbourne, Australia.
Andrew C LynchDepartment of Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia.
Alexander G HeriotDepartment of Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia.
Peter MacCallum Cancer Centre · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeRadical management of locally recurrent rectal cancer (LRRC) can lead to prolonged survival. This study aims to assess outcomes and identify prognostic factors for patients with LRRC treated using a multimodality treatment protocol.

methodsAn analysis of a prospectively maintained institutional database of consecutive patients who underwent radical surgical resection for LRRC was performed. Potential prognostic factors were investigated using a Cox proportional hazards model.

resultsNinety-eight patients were included in this study. A multimodality approach was taken in the majority, including preoperative chemoradiation (78%), intraoperative radiation therapy (47%) and adjuvant chemotherapy (41%). Extended resection was performed where required: bone resection (34%) and lateral pelvic sidewall dissection (31%). The rate of R0 resection was 66%. Estimated rates of 5-year overall survival (OS) and progression-free survival (PFS) were 41.8% (95% CI 32.5-53.7) and 22.5% (95% CI 15.3-33.1). On multivariate analysis, stage III disease at initial primary surgery, a positive margin at initial primary surgery, synchronous or previously resected oligometastases, a lateral or sacral invasive-type pelvic recurrence and the requirement for IORT all predicted for inferior PFS (p < 0.05). Eleven percent of patients subsequently underwent further pelvic surgery for pelvic re-recurrence and had an estimated 5-year OS rate of 54.5% (95% CI 29.0-100.0) from repeat surgery.

conclusionsRadical multimodality management of LRRC leads to prolonged survival in approximately 40% of patients. Those with sacral or lateral invasive-type recurrence or oligometastatic disease have inferior outcomes and further research is needed to optimise treatment for these groups.

Indexed as

AdultAgedAged, 80 and overChemoradiotherapyChemotherapy, AdjuvantCohort StudiesCombined Modality TherapyDisease-Free SurvivalFemaleHumansMaleMargins of ExcisionMiddle AgedNeoplasm Recurrence, LocalPrognosisProportional Hazards ModelsChemoradiotherapyOncological outcomeRectal cancer—local recurrenceSurvival

Identifiers

PMID29468354
OpenAlexW2793676962

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.